Extrachromosomal microDNA Signature as a Candidate Biomarker in Pediatric Acute Lymphoblastic Leukemia
Despite high cure rates, 10% to 15% of pediatric patients with ALL experience relapse. We identified a plasma-detectable microDNA signature from 11 genes that persists from diagnosis through relapse but disappears in remission. These findings demonstrate the potential of microDNA profiles as prognostic biomarkers in pediatric ALL, enabling noninvasive monitoring of disease status and risk stratification.
Authors
- Maja Krajinović (ORCID: https://orcid.org/0000-0003-4772-7031)
- Daniel Sinnett (ORCID: https://orcid.org/0000-0003-3625-6676)
- Ivan Brukner (ORCID: https://orcid.org/0000-0003-0225-9238)
- Alex Richard-St-Hilaire (ORCID: https://orcid.org/0009-0005-4718-0007)
- Pascal Tremblay-Dauphinais (ORCID: https://orcid.org/0009-0006-6052-3059)
- Claire Fuchs (ORCID: https://orcid.org/0000-0002-2202-907X)
- Teodor Veres
- Henrique Bittencourt (ORCID: https://orcid.org/0000-0002-5507-8310)
- Vincent Gagné (ORCID: https://orcid.org/0009-0008-3809-3771)
Institutions
- National Academies of Sciences, Engineering, and Medicine (US)
- Jewish General Hospital (CA)
- Centre Hospitalier Universitaire Sainte-Justine (CA)
- National Research Council Canada (CA)
- McGill University (CA)
- Université de Montréal (CA)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2025-12-11
- DOI
- https://doi.org/10.1158/2767-9764.crc-25-0419
- Primary Topic
- Acute Lymphoblastic Leukemia research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Leukemia and Lymphoma Society
- Centre de recherche du CHU Sainte-Justine
- Canadian Institutes of Health Research